(+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters

  title={(+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters},
  author={Richard B. Rothman and Robert D. Clark and John S. Partilla and Michael H Baumann},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={1191 - 1199}
(±)-Fenfluramine is an amphetamine analog that was once widely prescribed as an appetite suppressant. Although (±)-fenfluramine is no longer clinically available, the mechanisms underlying its anorectic properties are still of interest. Upon peripheral administration, stereoisomers of (±)-fenfluramine are N-deethylated to form the metabolites, (+)- and (-)-norfenfluramine. It is well accepted that isomers of (±)-fenfluramine and (±)-norfenfluramine interact with 5-hydroxytryptamine (serotonin… 

Figures and Tables from this paper

(+)-Norfenfluramine-Induced Arterial Contraction Is Not Dependent on Endogenous 5-Hydroxytryptamine or 5-Hydroxytryptamine Transporter

(+)-Norfenfluramine, the major metabolite of fenfluramine, causes vasoconstriction dependence on the 5-hydroxytryptamine (5-HT)2A receptor in rat. (+)-Norfenfluramine was reported as a

The Fenfluramine Metabolite (+)-Norfenfluramine Is Vasoactive

It is demonstrated for the first time that (+)-norfenfluramine is vasoactive and has the potential to increase blood pressure.

Evidence for a Role of Transporter-Mediated Currents in the Depletion of Brain Serotonin Induced by Serotonin Transporter Substrates

Comparisons of the pharmacology of several SERT substrates confirmed that drug-induced 5-HT release probably does not mediate 5- HT depletion, however, the magnitude of transporter-mediated inward current may be a critical factor in the cascade of events leading to5-HT deficits.

Amphetamine-like Neurochemical and Cardiovascular Effects of α-Ethylphenethylamine Analogs Found in Dietary Supplements

The results show that α-ethylphenethylamine analogs are biologically active, and although less potent than amphetamine, they produce cardiovascular effects that could pose risks to humans.

2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors

2-AI is predicted to have (+)-amphetamine-like effects and abuse potential whereas the ring-substituted derivatives may produce 3,4-methylenedioxymethamphetamine (MDMA)-like effects but with less abuse liability.

A Serotonin and Melanocortin Circuit Mediates d-Fenfluramine Anorexia

The results identify a neurochemically defined neural circuit through which d-Fen influences appetite and indicate that this 5-HT2CR/POMC-MC4R/SIM1 circuit may yield a more refined target to exploit for weight loss.

Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome

The results show that (+-FFA, (−)-FFA and (+)-norFFA displayed significant antiepileptic effects in the preclinical model, and thus can be considered as compounds actively contributing to the clinical efficacy of FFA.

N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability

Converging lines of evidence show that lengthening the N-alkyl substituent of 4-MA reduces potency to inhibit transporters, eliminates substrate activity at DAT and NET, and decreases abuse liability of the compounds.



Therapeutic and adverse actions of serotonin transporter substrates.

Indan Analogs of Fenfluramine and Norfenfluramine Have Reduced Neurotoxic Potential

In vitro and in vivo effects of d-fenfluramine: no apparent relation between 5-hydroxytryptamine release and hypophagia.

The results show that d-F is a potent 5-HT releaser also in the hypothalamus, one major site of action of the anorexigenic drug.

In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.

Using microdialysis in the hypothalamus of unanesthetized rats, evidence is provided that serotonin- (5-HT) selective and nonselective reuptake inhibitors can be distinguished from the 5-HT-releasing agent fenfluramine by four criteria.

Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications

It is suggested that all clinically available medications with serotonergic activity and their active metabolites be screened for agonist activity at 5-HT2B receptors and that clinicians should consider suspending their use of medications with significant activity at5-HT1B receptors.

Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension.

It is speculated that medications that are 5-HT transporter substrates get translocated into pulmonary cells where, depending on the degree of drug retention, their intrinsic drug toxicity, and individual susceptibility, PPH could develop as a response to high levels of these drugs or metabolites.